• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Liquid biopsy in tumors: opportunities and challenges.肿瘤中的液体活检：机遇与挑战。
Ann Transl Med. 2018 Nov;6(Suppl 1):S89. doi: 10.21037/atm.2018.11.31.
2
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges.胶质母细胞瘤中的液体活检：机遇、应用与挑战
Cancers (Basel). 2019 Jul 5;11(7):950. doi: 10.3390/cancers11070950.
3
Application of liquid biopsy in precision medicine: opportunities and challenges.液体活检在精准医学中的应用：机遇与挑战。
Front Med. 2017 Dec;11(4):522-527. doi: 10.1007/s11684-017-0526-7. Epub 2017 Jul 25.
4
[Liquid biopsy: opportunities and challenges of pathology].[液体活检：病理学的机遇与挑战]
Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):617-8.
5
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).cfDNA 分析在临床实践中的挑战与机遇：国际液体活检学会（ISLB）的观点。
Crit Rev Oncol Hematol. 2020 Jul;151:102978. doi: 10.1016/j.critrevonc.2020.102978. Epub 2020 May 5.
6
Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis.随着技术和生物信息学研究不断发展，液体活检的未来：单细胞水平分析在发现肿瘤异质性方面的机遇与挑战。
Cancer J. 2018 Mar/Apr;24(2):104-108. doi: 10.1097/PPO.0000000000000308.
7
Liquid biopsy for the detection and management of surgically resectable tumors.液体活检在可手术切除肿瘤的检测和管理中的应用。
Langenbecks Arch Surg. 2019 Aug;404(5):517-525. doi: 10.1007/s00423-019-01788-9. Epub 2019 Aug 5.
8
Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.循环肿瘤 DNA 和液体活检：检测技术的机遇、挑战和最新进展。
Lab Chip. 2018 Apr 17;18(8):1174-1196. doi: 10.1039/C8LC00100F.
9
Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978].《循环游离DNA分析在临床实践中的挑战与机遇：液体活检国际协会（ISLB）的观点》勘误 [《肿瘤学与血液学评论》151（7月）（2020）102978]
Crit Rev Oncol Hematol. 2020 Oct;154:103058. doi: 10.1016/j.critrevonc.2020.103058. Epub 2020 Aug 18.
10
[Liquid Biopsy: Challenges and Possibilities Regarding Its Clinical Application.].[液体活检：其临床应用面临的挑战与可能性。]
Rinsho Byori. 2016 May;64(4):394-399.

引用本文的文献

1
Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.用于早期癌症检测和诊断的新兴生物标志物：挑战、创新与临床前景
Eur J Med Res. 2025 Aug 18;30(1):760. doi: 10.1186/s40001-025-03003-6.
2
Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.液体活检——一篇叙述性综述及美国目前针对免疫疗法的政府临床试验的最新情况
Future Sci OA. 2025 Dec;11(1):2527598. doi: 10.1080/20565623.2025.2527598. Epub 2025 Aug 7.
3
Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice.妇科癌症中的液体活检：从分子洞察到精准肿瘤学及临床实践的转化框架
J Exp Clin Cancer Res. 2025 May 8;44(1):140. doi: 10.1186/s13046-025-03371-1.
4
Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.晚期胃癌的新兴治疗靶点与未来方向：综述
Cancers (Basel). 2024 Jul 29;16(15):2692. doi: 10.3390/cancers16152692.
5
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.用于预测肿瘤免疫检查点抑制剂疗效的生物标志物和计算模型。
Front Immunol. 2024 Mar 8;15:1368749. doi: 10.3389/fimmu.2024.1368749. eCollection 2024.
6
Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.蛋白质糖基化分析作为前列腺癌生物标志物：一项多国人群研究。
PLoS One. 2024 Mar 18;19(3):e0300430. doi: 10.1371/journal.pone.0300430. eCollection 2024.
7
Biogenesis, Isolation, and Detection of Exosomes and Their Potential in Therapeutics and Diagnostics.外泌体的生物发生、分离和检测及其在治疗和诊断中的潜力。
Biosensors (Basel). 2023 Aug 10;13(8):802. doi: 10.3390/bios13080802.
8
Liquid Biopsies: Emerging role and clinical applications in solid tumours.液体活检：在实体瘤中的新兴作用及临床应用
Transl Oncol. 2023 Sep;35:101716. doi: 10.1016/j.tranon.2023.101716. Epub 2023 Jun 14.
9
Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.液体活检在肺癌中的应用：复发和转移管理的生物标志物。
Int J Mol Sci. 2023 May 17;24(10):8894. doi: 10.3390/ijms24108894.
10
Extracellular Vesicles' Genetic Cargo as Noninvasive Biomarkers in Cancer: A Pilot Study Using ExoGAG Technology.细胞外囊泡的遗传物质作为癌症的非侵入性生物标志物：一项使用ExoGAG技术的初步研究
Biomedicines. 2023 Jan 30;11(2):404. doi: 10.3390/biomedicines11020404.

本文引用的文献

1
Enhanced detection of circulating tumor DNA by fragment size analysis.通过片段大小分析增强循环肿瘤 DNA 的检测。
Sci Transl Med. 2018 Nov 7;10(466). doi: 10.1126/scitranslmed.aat4921.
2
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
3
Progress in non-invasive detection of liver fibrosis.肝纤维化无创检测的进展
Cancer Biol Med. 2018 May;15(2):124-136. doi: 10.20892/j.issn.2095-3941.2018.0018.
4
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.癌症患者循环肿瘤 DNA 分析：美国临床肿瘤学会和美国病理学家学会联合审查。
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
5
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
6
Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.勘误：系统发育ctDNA分析描绘了早期肺癌的演变。
Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.
7
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.FDA 对奥希替尼治疗携带表皮生长因子受体 T790M 突变的转移性非小细胞肺癌的获益-风险评估。
Oncologist. 2018 Mar;23(3):353-359. doi: 10.1634/theoncologist.2017-0425. Epub 2017 Dec 14.
8
Avatars to personalized medicine: of mice and men.化身与个性化医疗：从小鼠到人类
Hepatobiliary Surg Nutr. 2017 Oct;6(5):347-349. doi: 10.21037/hbsn.2017.06.05.
9
A new link between innate immunity and hepatic metabolism: attractive unknown place to visit.固有免疫与肝脏代谢之间的新联系：值得探索的迷人未知领域。
Hepatobiliary Surg Nutr. 2017 Aug;6(4):264-267. doi: 10.21037/hbsn.2017.04.01.
10
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

Liquid biopsy in tumors: opportunities and challenges.

作者信息

Bai Yi, Zhao Haitao

机构信息

Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

出版信息

Ann Transl Med. 2018 Nov;6(Suppl 1):S89. doi: 10.21037/atm.2018.11.31.

DOI:10.21037/atm.2018.11.31
PMID:30613664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6291575/
Abstract
摘要